1. Home
  2. RPT vs ELTX Comparison

RPT vs ELTX Comparison

Compare RPT & ELTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RPT
  • ELTX
  • Stock Information
  • Founded
  • RPT 2014
  • ELTX 2011
  • Country
  • RPT United States
  • ELTX United States
  • Employees
  • RPT N/A
  • ELTX N/A
  • Industry
  • RPT
  • ELTX Biotechnology: Pharmaceutical Preparations
  • Sector
  • RPT
  • ELTX Health Care
  • Exchange
  • RPT NYSE
  • ELTX Nasdaq
  • Market Cap
  • RPT 121.7M
  • ELTX 121.7M
  • IPO Year
  • RPT N/A
  • ELTX N/A
  • Fundamental
  • Price
  • RPT $2.72
  • ELTX $8.09
  • Analyst Decision
  • RPT Strong Buy
  • ELTX Strong Buy
  • Analyst Count
  • RPT 1
  • ELTX 2
  • Target Price
  • RPT $4.00
  • ELTX $9.50
  • AVG Volume (30 Days)
  • RPT 399.6K
  • ELTX 48.3K
  • Earning Date
  • RPT 08-16-2025
  • ELTX 08-12-2025
  • Dividend Yield
  • RPT 8.81%
  • ELTX N/A
  • EPS Growth
  • RPT N/A
  • ELTX N/A
  • EPS
  • RPT N/A
  • ELTX N/A
  • Revenue
  • RPT N/A
  • ELTX N/A
  • Revenue This Year
  • RPT N/A
  • ELTX N/A
  • Revenue Next Year
  • RPT $19.21
  • ELTX N/A
  • P/E Ratio
  • RPT N/A
  • ELTX N/A
  • Revenue Growth
  • RPT N/A
  • ELTX N/A
  • 52 Week Low
  • RPT $2.29
  • ELTX $3.70
  • 52 Week High
  • RPT $3.86
  • ELTX $9.99
  • Technical
  • Relative Strength Index (RSI)
  • RPT N/A
  • ELTX 62.14
  • Support Level
  • RPT N/A
  • ELTX $7.76
  • Resistance Level
  • RPT N/A
  • ELTX $8.94
  • Average True Range (ATR)
  • RPT 0.00
  • ELTX 0.37
  • MACD
  • RPT 0.00
  • ELTX -0.03
  • Stochastic Oscillator
  • RPT 0.00
  • ELTX 51.09

About RPT RITHM PROPERTY TRUST INC

Rithm Property Trust Inc is a real estate investment trust (REIT) externally managed by an affiliate of Rithm Capital Corp. (Rithm). The group is embarking on a new commercial real estate-focused investment. Its tailored approach to investment management seeks to generate attractive risk-adjusted returns for stockholders over the long term through dividends and capital appreciation.

About ELTX Elicio Therapeutics Inc.

Elicio Therapeutics Inc is a clinical-stage biotechnology company pioneering the development of cancer immunotherapies for patients with limited treatment options and poor outcomes. Its proprietary Amphiphile, or AMP, platform delivers investigational immunotherapeutics directly to the brain center of the immune system the lymph nodes. Its focus is the development of cancer immunotherapies against biologically validated but hard-to-drug targets that can be activated through lymph node trafficking. Elicio is engineering lymph node-targeted AMPlifiers, immunomodulators, adjuvants, and vaccines for an array of aggressive cancers. It has developed its cancer vaccine product candidates to target biologically validated tumor mutation drivers using known neoantigens.

Share on Social Networks: